Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question.
Androgen deprivation therapy
Bipolar androgen therapy
Castration resistant prostate cancer
Testosterone
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
23
06
2022
accepted:
03
08
2022
pubmed:
20
8
2022
medline:
9
11
2022
entrez:
19
8
2022
Statut:
ppublish
Résumé
Whether or not androgen receptor (AR) axis could still be targetable in castration resistant prostate cancer (CRPC) patients with disease progression to next generation hormonal agents (NGHAs) is a controversial issue. Serum testosterone in CRPC patients has a positive prognostic role and increasing testosterone levels after androgen deprivation therapy (ADT) withdrawal or testosterone supplementation, as part of a bipolar androgen therapy (BAT) strategy, has been shown to potentially restore sensitivity to previous lines of NGHAs. These data suggest that maintenance of ADT in CRPC patients receiving further lines of treatment, as recommended by current international guidelines, could be questionable. Conversely, testosterone supplementation aimed to re-sensitize CRPC to further hormonal manipulation is a strategy worth to be explored in future clinical trials.
Identifiants
pubmed: 35986139
doi: 10.1007/s12020-022-03166-w
pii: 10.1007/s12020-022-03166-w
pmc: PMC9637055
doi:
Substances chimiques
Androgen Antagonists
0
Receptors, Androgen
0
Testosterone
3XMK78S47O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
441-445Informations de copyright
© 2022. The Author(s).
Références
Prostate. 2010 Oct 1;70(14):1600-7
pubmed: 20607766
Clin Endocrinol (Oxf). 2005 Oct;63(4):381-94
pubmed: 16181230
World J Mens Health. 2020 Apr;38(2):226-235
pubmed: 31190487
Cell Cycle. 2017 Sep 17;16(18):1639-1640
pubmed: 28820291
Best Pract Res Clin Endocrinol Metab. 2012 Aug;26(4):539-50
pubmed: 22863395
Endocrine. 2016 Dec;54(3):830-833
pubmed: 26690656
J Clin Oncol. 1993 Nov;11(11):2167-72
pubmed: 8229130
Urol Oncol. 2022 Jan;40(1):4.e19-4.e28
pubmed: 34548234
J Clin Oncol. 1994 Sep;12(9):1868-75
pubmed: 8083710
Clin Genitourin Cancer. 2015 Feb;13(1):10-6
pubmed: 25242417
Andrology. 2020 Nov;8(6):1504-1505
pubmed: 33460316
J Endocrinol Invest. 2005;28(10 Suppl):73-9
pubmed: 16550728
Eur Urol. 2015 Jul;68(1):147-53
pubmed: 25457020
Prostate. 2012 Oct 1;72(14):1491-505
pubmed: 22396319
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
Am J Clin Oncol. 2011 Apr;34(2):140-4
pubmed: 20686407
Eur J Cancer. 2021 Sep;155:127-135
pubmed: 34371442
Clin Endocrinol (Oxf). 2005 Sep;63(3):280-93
pubmed: 16117815
Expert Opin Biol Ther. 2007 Jul;7(7):1093-106
pubmed: 17665996
N Engl J Med. 2019 Dec 26;381(26):2506-2518
pubmed: 31566937
Aging Male. 2021 Dec;24(1):119-138
pubmed: 34396893
Handb Exp Pharmacol. 2018;249:181-194
pubmed: 28353036
Clin Genitourin Cancer. 2018 Jun;16(3):165-175.e2
pubmed: 29454638
J Clin Oncol. 2021 Apr 20;39(12):1371-1382
pubmed: 33617303